<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Multiple Myeloma via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 5000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Multiple Myeloma' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Multiple+Myeloma&t=Multiple+Myeloma&s=Search&f=source]]></link>
        <lastBuildDate>Sat, 16 Aug 2008 14:45:21 +0100</lastBuildDate>
        <item>
            <title>Fgfr3 ?!@: why should a myeloma patient care to know about it ?</title>
            <link>http://feeds.feedburner.com/~r/Myeloma-cse/~3/155455809/fgfr3-why-should-myeloma-patient-care.html</link>
            <description>FGFR3 stands for Fibroblast Growth Factor receptor 3. In a recent study by the lead author Sumin Kang, a Postdoctral Fellow at Emory Winship Cancer Institute , have found a potential target for new drug development for multiple myeloma and other cancers like human bladder and cervical malignancies where abnormal FGFR3 is implicated in their causation pathways.   The press release is here and the published article in PubMed search engine is here . The senior author Dr. Jing Chen is an assistant professor of Hematology and Oncology at Emory Winship and also a Georgia Cancer Coalition Distinguished Cancer Scholar. Learn about the steps involved in development of a new drug here at this forum on Alzheimer research forum website.Watch this video on prospects of new drug development in Multiple Myeloma, featuring specialists from MyelomaUK &amp; St Vincent's Comprehensive Cancer Center , Manhattan, NY, USA.You have subscribed to http://myeloma-cse.blogspot.com (Source: Multiple Myeloma)</description>
            <author>Multiple Myeloma</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=865797</comments>
            <pubDate>Wed, 12 Sep 2007 09:28:00 +0100</pubDate>
            <guid isPermaLink="false">865797</guid>        </item>
        <item>
            <title>Profile: dr. s v rajkumar</title>
            <link>http://feeds.feedburner.com/~r/Myeloma-cse/~3/154940087/profile-dr-s-v-rajkumar.html</link>
            <description>While surfing the net for new information on myeloma, it is natural to come across some names  repeatedly. One such name is Dr. S V Rajkumar, MD. He is Professor of Hematology and Laboratory Medicine and Pathology at the prestigious Mayo Clinic.One of his research interests includes developing new therapies for Multiple Myeloma. It is an important area of current myeloma research. With novel regimens and novel drugs available in market there is hope for the myeloma patients.We can see Dr. Rajkumar discussing the results of a Phase III trial of combination of lenalidomide (Revlimid by Celgene) plus high dose dexamethasone versus lenalidomide plus low dose dexamethasone His team has currently initiated the Phase II multi-center 4 drug combination trial looking at efficacy of combining bortezomib (Velcade by Millennium Pharmaceuticals, Inc), lenalidomide (Revlimid) and dexamethasone with or without cyclophosphamide as front-line therapy of multiple myeloma. This news can be found here.     As a newly diagnosed multiple myeloma patient one may be esp. interested in this trial and may take the benefit of this multi-center  trial if found eligible. Dr. Rajkumar's profile can be seen here.    His list of scientific publications can be found here. (Source: Multiple Myeloma)</description>
            <author>Multiple Myeloma</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=864631</comments>
            <pubDate>Tue, 11 Sep 2007 07:36:00 +0100</pubDate>
            <guid isPermaLink="false">864631</guid>        </item>
        <item>
            <title>Stay uptodate with myeloma</title>
            <link>http://feeds.feedburner.com/~r/Myeloma-cse/~3/154508625/stay-uptodate-with-myeloma.html</link>
            <description>Hi Folks,In line with my effort to bring latest information about myeloma available to you, I am going to show you a couple of easy ways to do it.1) PubMed Search:PubMed :  is a great database of medical information on net. It is offered free to public by the US National Library of medicine. It is rightly the world's largest medical library.It is of utmost importance to doctors as they use this service to keep themselves uptodate with the latest information in their field. As a patient affected with this yet incurable disease, you can also get yourself educated about the new approaches being developed by the clinicians, scientists and researchers in this area. You may want to approach them in case their work interests you.But as you know, it is difficult to keep up with the amazing proliferation of biomedical information on a daily basis. Here, the RSS (Real Simple Syndication) technology and PubMed can come to your help.I will illustrate this through a simple search for &quot;myeloma&quot; on PubMed.Click &quot;Go&quot; after entering Myeloma into the field as shown.As of today as I write this at 3:14 am CST USA, the next screen should appear like this.Wheewww, it returns 34022 articles to read which contains the terms &quot;myeloma&quot; anywhere within the text of the scientific articles maintained in PubMed database. Well, do not worry, as all these result articles are from way back into 1950s to till date. We are interested in the new information available in this area. So, now I want you to focus on two things here.1) Save Search: Button besides the &quot;Clear&quot; button. On clicking this Save Search button, it opens a new pop up window, wherein you can enter your email address. (Assuming that you are logged into MyNCBI already. If you have not registered for MyNCBI, register yourself with an email id and its free.) It also gives you various options as to how you want to be notified whenever a new result comes up containing your search term. This function saves you the labor of performing PubMed search on their website, instead you get all the new results right in your email!2) RSS: But better still I would prefer the newer technology called RSS. Please take note of the &quot;drop down&quot; menu containing term &quot;Send to&quot; . If you click it, you will see an option of &quot;RSS Feed&quot;. Select this &quot;RSS Feed&quot; and you will come across a screen like this:Here it gives you an option of choosing the number of items in your RSS feed.Well for a disease like myeloma, I am happy with 15 posts. (If you want to search say in different area which has more action going on like say e.g. diabetes , hypertension, I believe 15 items would be very less number given the vast amount of work being done in the area. )Click &quot;Create Feed&quot; and you see this:Click the Orange XML icon. It should open up a new pop-up window. Copy the URL in the address bar of new pop up window. We will paste this  Link into  a  RSS reader like  say e.g. Google Reader.  There are a variety of  readers available for free  on the web. But  since I personally use  Google more, I use  Google Reader service for managing my RSS subscriptions.If one has Gmail account, you will find the Reader service as shown in the link here:On the Reader service, look for a way to &quot;Add Subscription&quot; .On clicking it: Paste the URL into the box as shown here:Click &quot;Add&quot;. Now you will successfully receive the latest results on myeloma as and when new information gets updated in PubMed!!The RSS makes all the steaming latest news come to you !! So use the power of new technology to keep yourself updated. I will write on another useful disease specific RSS service &quot;Medworm&quot; in next blog. (Source: Multiple Myeloma)</description>
            <author>Multiple Myeloma</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=864632</comments>
            <pubDate>Mon, 10 Sep 2007 06:36:00 +0100</pubDate>
            <guid isPermaLink="false">864632</guid>        </item>
    </channel>
</rss>
